[go: up one dir, main page]

BRPI0416566A - tratamento de fenilcetonúrias com bh4 - Google Patents

tratamento de fenilcetonúrias com bh4

Info

Publication number
BRPI0416566A
BRPI0416566A BRPI0416566-7A BRPI0416566A BRPI0416566A BR PI0416566 A BRPI0416566 A BR PI0416566A BR PI0416566 A BRPI0416566 A BR PI0416566A BR PI0416566 A BRPI0416566 A BR PI0416566A
Authority
BR
Brazil
Prior art keywords
compositions
treatment
phenylketonuria
phenylketonuria treatment
phenyletonuries
Prior art date
Application number
BRPI0416566-7A
Other languages
English (en)
Inventor
Dan Oppenheimer
Emil D Kakkis
Frederic D Price
Alejandro Dorenbaum
Original Assignee
Biomarin Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34619513&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0416566(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biomarin Pharm Inc filed Critical Biomarin Pharm Inc
Publication of BRPI0416566A publication Critical patent/BRPI0416566A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A23L33/155—Vitamins A or D
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"TRATAMENTO DE FENILCETONúRIAS COM BH4". A presente invenção é voltada a métodos e composições inéditos para a intervenção terapêutica em hiperfenilalaninemia. Mais especificamente, a especificação descreve métodos e composições para o tratamento de diversos tipos de fenilcetonúrias usando-se composições que compreendem BH4. São contempladas as terapias de combinação de BH4 com outros regimes terapêuticos.
BRPI0416566-7A 2003-11-17 2004-11-17 tratamento de fenilcetonúrias com bh4 BRPI0416566A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52076703P 2003-11-17 2003-11-17
PCT/US2004/038296 WO2005049000A2 (en) 2003-11-17 2004-11-17 Treatment of phenylketonurias with bh4

Publications (1)

Publication Number Publication Date
BRPI0416566A true BRPI0416566A (pt) 2007-01-23

Family

ID=34619513

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0416566-7A BRPI0416566A (pt) 2003-11-17 2004-11-17 tratamento de fenilcetonúrias com bh4

Country Status (18)

Country Link
US (6) US7566714B2 (pt)
EP (3) EP3138566B1 (pt)
JP (2) JP2007511536A (pt)
KR (1) KR20070005550A (pt)
CN (1) CN1905863B (pt)
AU (1) AU2004291149C1 (pt)
BR (1) BRPI0416566A (pt)
CA (1) CA2545584C (pt)
CY (2) CY1118171T1 (pt)
DK (2) DK3138566T3 (pt)
ES (2) ES2905305T4 (pt)
HU (2) HUE029533T2 (pt)
IL (1) IL175529A (pt)
MX (1) MXPA06005451A (pt)
PL (2) PL3138566T3 (pt)
PT (2) PT1708690T (pt)
SI (1) SI3138566T1 (pt)
WO (1) WO2005049000A2 (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005049000A2 (en) 2003-11-17 2005-06-02 Biomarin Pharmaceutical Inc. Treatment of phenylketonurias with bh4
WO2006055511A2 (en) * 2004-11-17 2006-05-26 Biomarin Pharmaceutical Inc. Stable tablet formulation of tetrahydrobiopterin
WO2007072911A1 (ja) * 2005-12-22 2007-06-28 Asubio Pharma Co., Ltd. 塩酸サプロプテリンの生体内吸収性を向上させた製剤
US20100234385A1 (en) * 2006-03-20 2010-09-16 Kaneka Corporation Compsition Containing Biopterin and Method for Using The Same
CA2675134A1 (en) * 2007-01-12 2008-07-24 Biomarin Pharmaceutical Inc. Pterin analogs
KR20100016445A (ko) 2007-04-11 2010-02-12 바이오마린 파머수티컬 인크. 테트라하이드로바이오프테린 투여 방법, 관련 조성물 및 측정 방법
US20080275726A1 (en) * 2007-05-02 2008-11-06 Steven Yannicelli System and method for metabolic patient management and treatment
MX2010006025A (es) 2008-01-03 2010-06-30 Biomarin Pharm Inc Analogo de pterina para tratar afeccion sensible a bh4.
JP2011508781A (ja) * 2008-01-07 2011-03-17 ビオマリン プハルマセウトイカル インコーポレイテッド テトラヒドロビオプテリンの合成方法
UA102128C2 (en) * 2008-12-05 2013-06-10 Х. Луннбек А/С Nalmefene hydrochloride dihydrate
CA2764571C (en) * 2009-06-12 2018-12-18 Wisconsin Alumni Research Foundation Glycomacropeptide medical foods for nutritional management of phenylketonuria and other metabolic disorders
IT1399244B1 (it) * 2009-07-31 2013-04-11 Pharmarte S R L Formulazione di barretta specifica per la gravidanza.
EP2601946A1 (en) * 2011-12-06 2013-06-12 Pécsi Tudomànyegyetem Treatment and prevention of diseases related to oxidative stress
US9216178B2 (en) 2011-11-02 2015-12-22 Biomarin Pharmaceutical Inc. Dry blend formulation of tetrahydrobiopterin
WO2014018873A2 (en) 2012-07-27 2014-01-30 Chemic Laboratories Inc. Compositions comprising folic acid derivatives. their preparations and methods of use
US9982242B2 (en) * 2012-11-09 2018-05-29 Sanyo Foods Co., Ltd. Protein complex capable of catalyzing asymmetric oxidation reaction and method for producing same
CN105658242A (zh) 2013-10-22 2016-06-08 夏尔人类遗传性治疗公司 用于苯丙酮尿症的mrna疗法
AU2016206208A1 (en) 2015-01-09 2017-08-10 Mcmaster University Allosteric activators for treatment of phenylketonuria
WO2017027462A1 (en) * 2015-08-07 2017-02-16 Children's National Medical Center Treatment for the fetus with congenital heart disease
US20190167598A1 (en) 2016-07-29 2019-06-06 Dipharma S.A. A novel treatment regimen involving sapropterin dihydrochloride
WO2018102314A1 (en) * 2016-11-29 2018-06-07 Censa Pharmaceuticals Inc. Polymorphic form of sepiapterin
KR102789662B1 (ko) * 2016-11-29 2025-04-03 피티씨 테라퓨틱스 엠피, 인크. 세피아프테린의 다형체 및 그의 염
BR112020003865A8 (pt) 2017-09-01 2022-08-16 Censa Pharmaceuticals Inc Composições farmacêuticas compreendendo sepiapterina e seus usos
IT201700099690A1 (it) * 2017-09-06 2019-03-06 Abiogen Pharma Spa Composizione per l’integrazione di calcio
CN107751998A (zh) * 2017-09-29 2018-03-06 赤峰禾士营养食品科技有限公司 一种用于苯丙酮尿症患者的食用配方粉
WO2019232126A1 (en) 2018-05-30 2019-12-05 Censa Pharmaceuticals Inc. Compositions and methods for increasing tetrahydrobiopterin plasma exposure
WO2019232130A1 (en) 2018-05-30 2019-12-05 Censa Pharmaceuticals Inc. Methods for increasing sepiapterin plasma exposure
MA54936A (fr) * 2019-02-14 2021-12-22 Som Innovation Biotech S A Triamtérène ou nolatrexed destinés à être utilisés dans le traitement de la phénylcétonurie
TR201914416A1 (tr) * 2019-09-23 2021-04-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Sapropteri̇n di̇hi̇droklorürün efervesan formülasyonlari
CN112362785B (zh) * 2020-11-19 2022-12-27 南京工业大学 一组诊断标志物在诊断精索静脉曲张所致弱精子症中的应用
AU2021406035A1 (en) * 2020-12-21 2023-06-22 Oxford University Innovation Limited Treatment of disorders associated with low bh4 bioavailability
CN114569607B (zh) * 2022-02-28 2024-02-13 军事科学院军事医学研究院环境医学与作业医学研究所 5-羟色氨酸在制备改善高原低氧所致雌性生理周期紊乱保健品或药物中的应用

Family Cites Families (158)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US452822A (en) * 1891-05-26 Cultivator and seed-planter
US810A (en) 1838-06-27 Amokyamsden
US5902A (en) 1848-11-07 Universal instrument-sharpener
US2603643A (en) 1947-03-13 1952-07-15 Hoffmann La Roche 2-amino-4-hydroxy-6-polyhydroxyalkyl pteridine and methods of oxidizing same
US2601215A (en) 1948-03-17 1952-06-17 American Cyanamid Co Process of preparing dihydropterins
US2541717A (en) 1948-10-18 1951-02-13 Upjohn Co Pterine imines
US2568685A (en) * 1950-07-22 1951-09-18 Upjohn Co 2-amino-4-hydroxy-6-omega-carboxytrihydroxy-propylpteridines
US2955110A (en) 1955-01-13 1960-10-04 American Cyanamid Co Substituted pteridines and method of preparing the same
US3505329A (en) 1968-02-06 1970-04-07 Smithkline Corp Process for the synthesis of biopterin
JPS5399971A (en) 1977-02-12 1978-08-31 Nec Corp Satellite posture detecting system
JPS5921685Y2 (ja) 1979-02-27 1984-06-27 松下電器産業株式会社 ガス炊飯器
GB2056459B (en) 1979-07-04 1983-03-09 Daiichi Radioisotope Lab Pterin derivatives and an assay method for determining pterins
US4252822A (en) 1979-12-26 1981-02-24 Children's Hospital Medical Center Method for treating phenylketonuria
JPS5726123A (en) 1980-07-25 1982-02-12 Hitachi Metals Ltd Production of hardened piston ring made of steel
JPS5883691A (ja) 1981-11-13 1983-05-19 Kanegafuchi Chem Ind Co Ltd １′，２′−ジアシル−（６ｒ，ｓ）−５，６，７，８−テトラヒドロ−ｌ−ビオプテリンおよびその製法
JPS5925323A (ja) 1982-03-03 1984-02-09 鐘淵化学工業株式会社 プテリン誘導体からなる脳内神経伝達物質の関わる疾病の治療剤
JPS5921685A (ja) 1982-07-28 1984-02-03 Suntory Ltd Ｌ―エリスロ―バイオプテリンの製造法
GB8318833D0 (en) 1983-07-12 1983-08-10 Wellcome Found Chemical compounds
JPS5976086A (ja) * 1982-09-20 1984-04-28 ザ　ウエルカム　フアウンデ−シヨン　リミテツド プテリジン化合物
DK426083A (da) * 1982-09-20 1984-03-21 Wellcome Found Pteriner, fremgangsmaader til deres fremstilling samt deres anvendelse
JPS5982091A (ja) 1982-10-29 1984-05-11 Suntory Ltd バイオプテリンの製法
JPS6011581Y2 (ja) 1982-11-12 1985-04-17 古河電気工業株式会社 プリント回路板用リセプタクル
JPS5982091U (ja) 1982-11-26 1984-06-02 株式会社バンダイ 吸着盤付走行玩具
US5196533A (en) 1983-04-11 1993-03-23 South Alabama Medical Science Foundation, Usa Cyclization of 5 amino-pyrimidines to quinoid 6,6 disubstituted dihydropteridines
US4587340A (en) 1983-09-19 1986-05-06 Burroughs Wellcome Co. Biopterin analogs
JPS60178887A (ja) * 1984-02-23 1985-09-12 Kanegafuchi Chem Ind Co Ltd ５，６，７，８−テトラヒドロ−ｌ−ビオプテリンの製造法
JPS60199889A (ja) 1984-03-24 1985-10-09 Kanegafuchi Chem Ind Co Ltd ５，６，７，８−テトラヒドロ−ｌ−エリスロ−ビオプテリンの硫酸塩およびその製法
JPS60204786A (ja) 1984-03-29 1985-10-16 Univ Nagoya （６ｒ）―テトラヒドロビオプテリンの合成法
US4550109A (en) * 1984-05-31 1985-10-29 The Board Of Regents, The University Of Texas System Lipoidal biopterin compounds
DE3437944A1 (de) 1984-10-17 1986-07-31 Biotest-Serum-Institut Gmbh, 6000 Frankfurt Verwendung von pterinen zur steigerung der aktivitaet von lymphokinen und anderen blutfaktoren, sowie ein diagnostisches oder therapeutisches praeparat, das pterine in kombination mit lymphokinen enthaelt
US4713454A (en) * 1985-01-28 1987-12-15 Shiratori Pharmaceutical Co., Ltd. Preparation process of (6R)-tetrahydro-L-biopterin
JPS61277618A (ja) 1985-06-04 1986-12-08 Suntory Ltd 自閉症治療剤
US4707361A (en) 1985-08-02 1987-11-17 Stauffer Chemical Company Granular anhydrous dicalcium phosphate compositions suitable for direct compression tableting
JPH0692302B2 (ja) 1986-09-02 1994-11-16 鐘淵化学工業株式会社 神経病治療剤
EP0278040B1 (de) * 1987-02-13 1991-08-14 Pharm-Allergan Gmbh Verwendung von Pteridinen und/oder Purinen oder eines Xanthinoxidase-Hemmers zur Herstellung eines Arzneimittels zur Behandlung von genetisch bedingten degenerativen Netzhauterkrankungen
DE3853711T2 (de) 1987-11-30 1996-01-11 Vitamin Kenkyusho Kk Zwischenverbindungen für die Synthese von 5,6,7,8-Tetrahydro-L-erythro-biopterin und seiner Derivate.
EP0349204A3 (en) 1988-06-28 1991-08-07 Bend Research, Inc. Use and regeneration of reagents using coupled reactions and permselective barriers
GB8823804D0 (en) * 1988-10-11 1988-11-16 Holgates Nutritional Foods Ltd Proteinaceous composition
JP2843592B2 (ja) * 1989-02-28 1999-01-06 日清製粉株式会社 Ｌ−リボース誘導体
US5006344A (en) 1989-07-10 1991-04-09 E. R. Squibb & Sons, Inc. Fosinopril tablet formulations
US5554647A (en) * 1989-10-12 1996-09-10 Perricone; Nicholas V. Method and compositions for treatment and/or prevention of skin damage and aging
WO1991012814A1 (en) * 1990-02-28 1991-09-05 E.I. Du Pont De Nemours And Company Activation of monocyte/macrophages
DE4037447C2 (de) * 1990-11-24 1994-06-01 Milupa Ag Phenylalaninfreies Diätetikum für juvenile und adulte Personen mit Phenylketonurie sowie ein Verfahren zu seiner Herstellung
JPH04210624A (ja) * 1990-12-11 1992-07-31 Shigenobu Sakata 薬用効果を有する入浴剤及び化粧水
US5194469A (en) * 1991-02-28 1993-03-16 The Goodyear Tire & Rubber Company Latex for coatings having improved flexibility
WO1992019228A1 (en) 1991-04-29 1992-11-12 Merck & Co., Inc. Optimized tablet formulation
US5500013A (en) 1991-10-04 1996-03-19 Scimed Life Systems, Inc. Biodegradable drug delivery vascular stent
DE69229270D1 (en) * 1991-11-16 1999-07-01 Suntory Ltd Rezeptor für 6(r)-l-erythro-5,6,7,8-tetrahydrobiopterin
US5877176A (en) 1991-12-26 1999-03-02 Cornell Research Foundation, Inc. Blocking induction of tetrahydrobiopterin to block induction of nitric oxide synthesis
JP2534423B2 (ja) 1991-12-26 1996-09-18 コーネル・リサーチ・ファンデーション・インコーポレイテッド 酸化窒素の過剰生産から生じる血管失調を阻止する阻害剤
US5198547A (en) 1992-03-16 1993-03-30 South Alabama Medical Science Foundation, Usa Process for N5-formylating tetrahydropteridines
DE4215275A1 (de) * 1992-05-09 1993-11-11 Merck Patent Gmbh Mittel und Verfahren zur Behandlung von Körperflüssigkeiten bei der Bestimmung von Neopterin
US6251953B1 (en) * 1992-10-30 2001-06-26 Andrew Brookner Beta-carotene therapy of individuals having abnormal immunological and serological indices, and individuals having infections and diseases causing changes therein
US20020061862A1 (en) * 1992-11-25 2002-05-23 University Of Pittsburgh Of The Commonwealth System Of Higher Education Inducible nitric oxide synthase for treatment of disease
WO1994012645A2 (en) * 1992-11-25 1994-06-09 University Of Pittsburgh Of The Commonwealth System Of Higher Education cDNA CLONE FOR HUMAN INDUCIBLE NITRIC OXYDE SYNTHASE AND PROCESS FOR PREPARING SAME
US5830461A (en) * 1992-11-25 1998-11-03 University Of Pittsburgh Of The Commonwealth System Of Higher Education Methods for promoting wound healing and treating transplant-associated vasculopathy
US5658565A (en) * 1994-06-24 1997-08-19 University Of Pittsburgh Of The Commonwealth System Of Higher Education Inducible nitric oxide synthase gene for treatment of disease
US5468772A (en) * 1993-03-10 1995-11-21 Pharmagenesis, Inc. Tripterinin compound and method
PT689449E (pt) * 1993-03-19 2003-03-31 Vacsyn Sa Composicoes para aplicacao em terapeutica humana caracterizadas pela associacao de um peptido de muramilo a uma citoquina
DE4308739C1 (de) 1993-03-19 1994-06-23 Henning Berlin Gmbh Pterinderivate, ihre Herstellung und ihre Verwendung
US5449688A (en) * 1993-03-30 1995-09-12 The United States Of America As Represented By The Department Of Health And Human Services Method of treating chronic inflammatory diseases
CH686369A5 (de) 1994-05-09 1996-03-15 Eprova Ag Stabile kristalline (6S)- und (6R)-Tetrahydrofolseure.
US5945452A (en) 1993-06-11 1999-08-31 The Board Of Trustees Of The Leland Stanford Junior University Treatment of vascular degenerative diseases by modulation of endogenous nitric oxide production or activity
WO1995013075A1 (en) 1993-11-12 1995-05-18 Cell Therapeutics, Inc. Method for preventing tissue injury from hypoxia
US5502050A (en) 1993-11-29 1996-03-26 Cornell Research Foundation, Inc. Blocking utilization of tetrahydrobiopterin to block induction of nitric oxide synthesis
TW282398B (pt) * 1993-12-22 1996-08-01 Bristol Myers Squibb Co
WO1995028377A1 (en) 1994-04-18 1995-10-26 Abbott Laboratories Guanidine compounds as regulators of nitric oxide synthase
DE4418096A1 (de) 1994-05-24 1995-11-30 Cassella Ag Verwendung von Pteridin-Derivaten als Hemmstoffe der NO-Synthase
US5753656A (en) 1994-08-05 1998-05-19 Suntory Limited Method for treating spinocerebellar degeneration
US5516532A (en) 1994-08-05 1996-05-14 Children's Medical Center Corporation Injectable non-immunogenic cartilage and bone preparation
US5643586A (en) * 1995-04-27 1997-07-01 Perricone; Nicholas V. Topical compositions and methods for treatment of skin damage and aging using catecholamines and related compounds
US5799283A (en) * 1995-05-10 1998-08-25 Francisco; Paul A. Point of sale governmental sales and use tax reporting and receipt system
US5744340A (en) * 1995-06-09 1998-04-28 Schering Corporation Expression of human inducible nitric oxide synthase
SE506533C2 (sv) * 1995-07-03 1998-01-12 Birger Andersson En process för in vitro analys av substansers toxiska och allergena egenskaper samt användning av neopterin för att skilja mellan allergiska immunreaktioner
EP0854934A4 (en) * 1995-08-18 2000-09-06 Donald W Landry DETECTION OF ORGANIC COMPOUNDS BY REGULATION OF ANTIBODY CATALYZED REACTIONS
US5879690A (en) * 1995-09-07 1999-03-09 Perricone; Nicholas V. Topical administration of catecholamines and related compounds to subcutaneous muscle tissue using percutaneous penetration enhancers
DE19534602C2 (de) * 1995-09-18 1999-09-09 Milupa Ag Verwendung von Threonin zur Behandlung der Phenylketonurie
US5811437A (en) 1996-05-21 1998-09-22 Eli Lilly And Company Methods of increasing nitric oxide synthesis
JP2711828B2 (ja) 1996-06-25 1998-02-10 白鳥製薬株式会社 （６ｒ）−テトラヒドローｌ−バイオプテリン塩酸塩の製造法
US20020076782A1 (en) 1996-07-05 2002-06-20 John P.N. Rosazza Purified nitric oxide synthase
US5856158A (en) * 1996-07-05 1999-01-05 University Of Iowa Research Foundation Purified nitric oxide synthase from rat brain
EP0884317B1 (en) 1996-07-31 2005-05-18 Cmic Co., Ltd. Active oxygen scavengers containing pterin derivatives
GB9617990D0 (en) 1996-08-29 1996-10-09 Scotia Holdings Plc Treatment of pain
PT923315E (pt) * 1996-08-30 2004-04-30 Nestle Sa Formula nutricional para pacientes com fenilcetonuria
EP0908182B2 (en) 1996-08-30 2007-03-28 Daiichi Asubio Pharma Co., Ltd. Preventives or remedies for diseases induced by hypofunction of nitric oxide synthase (nos)
AU6237798A (en) * 1996-12-24 1998-07-17 Research Development Foundation Ricin inhibitors and methods for use thereof
US6562969B1 (en) * 1996-12-24 2003-05-13 Research Development Foundation Ricin inhibitors and methods for use thereof
US6428990B1 (en) * 1997-04-11 2002-08-06 Abbott Laboratories Human desaturase gene and uses thereof
US5846775A (en) 1997-04-22 1998-12-08 Incyte Pharmaceuticals, Inc. GTP cyclohydrolase I regulatory protein
CH693255A5 (de) 1997-06-13 2003-05-15 Eprova Ag Verwendung von Tetrahydrofolaten in der natürlichenstereoisomeren Form zur Herstellung einer pharmazeutischenZubereitung geeignet zur Beeinflussung des Homocystein-Spiegels.
US5922713A (en) 1997-06-26 1999-07-13 Werner; Ernst Inhibition of nitric oxide synthase
AU1189399A (en) * 1997-10-15 1999-05-03 Uab Research Foundation Bathocuproine treatment of neurologic disease
EP1004308B1 (en) 1998-02-27 2005-05-11 Daiichi Suntory Pharma Co., Ltd. Preventives or remedies for drug-induced renal disturbance
JP4306825B2 (ja) 1998-02-27 2009-08-05 アスビオファーマ株式会社 インスリン抵抗性が関与する血管機能異常を伴う疾患の予防または治療剤
US6180597B1 (en) * 1998-03-19 2001-01-30 Brigham And Women's Hospital, Inc. Upregulation of Type III endothelial cell nitric oxide synthase by rho GTPase function inhibitors
US6162914A (en) 1998-04-24 2000-12-19 Cerbios-Pharma S.A. Process for the reduction of pterins
US6117872A (en) * 1998-06-23 2000-09-12 The Board Of Trustees Of The Leland Stanford Junior University Enhancement of exercise performance by augmenting endogenous nitric oxide production or activity
AU4990599A (en) 1998-07-14 2000-02-07 Brigham And Women's Hospital Upregulation of type iii endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization
US6423751B1 (en) * 1998-07-14 2002-07-23 The Brigham And Women's Hospital, Inc. Upregulation of type III endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization
US6656925B2 (en) * 1998-09-09 2003-12-02 Advanced Medical Instruments Composition and method of treating arthritis
US6346519B1 (en) * 1998-09-09 2002-02-12 Advanced Medical Instruments Method and composition for treating arthritis
WO2000037653A1 (en) 1998-12-22 2000-06-29 Board Of Regents, The University Of Texas System Structural basis for pterin function in nitric oxide synthase
US7276506B2 (en) * 1998-12-28 2007-10-02 4 Aza Bioscience Nv Immunosuppressive effects of pteridine derivatives
US6319905B1 (en) 1998-12-29 2001-11-20 Cell Genesys, Inc. Method of controlling L-Dopa production and of treating dopamine deficiency
HU229441B1 (en) * 1999-01-08 2013-12-30 3M Innovative Properties Co Formulations and methods for treating mucosal associated conditions with an immune response modifier
US6486168B1 (en) 1999-01-08 2002-11-26 3M Innovative Properties Company Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
US20020058674A1 (en) * 1999-01-08 2002-05-16 Hedenstrom John C. Systems and methods for treating a mucosal surface
US6200758B1 (en) 1999-02-19 2001-03-13 New York State Office Of Mental Health Phenylalanine hydroxylase gene variants, and amino acid and pterin homeostasis, in the definition, detection, treatment and prevention of psychotic, mood and personality disorders
CA2368187A1 (en) 1999-03-19 2000-09-28 Brigham And Women's Hospital, Inc. Upregulation of type iii endothelial cell nitric oxide synthase by hmg-coa reductase inhibitors
AU4013900A (en) 1999-03-19 2000-10-09 Enos Pharmaceuticals, Inc. Increasing cerebral bioavailability of drugs
CH693905A5 (de) 1999-04-15 2004-04-15 Eprova Ag Stabile kristalline Salze von 5-Methyltetrahydrofolsäure.
US6288535B1 (en) * 1999-07-06 2001-09-11 Jacob Chass Hall effect, shaft angular position sensor with asymmetrical rotor
CA2380072C (en) * 1999-07-28 2007-07-10 John Cooke Nicotine in therapeutic angiogenesis and vasculogenesis
GB2355191A (en) 1999-10-12 2001-04-18 Laxdale Ltd Combination formulations for fatigue, head injury and strokes
US20020155445A1 (en) * 1999-12-16 2002-10-24 Jarvik Jonathan W. Methods and products for peptide based DNA sequence identification and analysis
SE0000307D0 (sv) 2000-01-31 2000-01-31 Univ Zuerich Method and formulation för treatment of vasoconstriction
ATE312613T1 (de) 2000-02-29 2005-12-15 Bristol Myers Squibb Co Niedrig dosierte entecavir formulierung und deren verwendung
AUPQ598300A0 (en) * 2000-03-03 2000-03-23 Citrus Sensation Pty Ltd Citrus fruit preservative
US6576105B1 (en) * 2000-03-31 2003-06-10 Truman State University Pteridine analysis by capillary electrophoresis using laser-induced fluorescence detection
CA2404909A1 (en) * 2000-04-12 2001-10-25 Caroline L. Jones Pharmacotherapy for vascular dysfunction associated with deficient nitric oxide bioactivity
US6544994B2 (en) * 2000-06-07 2003-04-08 Eprov Ag Pharmaceutical preparation for treating or preventing cardiovascular or neurological disorders by modulating of the activity of nitric oxide synthase
WO2002000933A2 (en) * 2000-06-23 2002-01-03 Interleukin Genetics, Inc. Screening assays for identifying modulators of the inflammatory or immune responses
AU2001284865A1 (en) * 2000-08-14 2002-02-25 Joan M. Fallon Methods for diagnosing and treating dysautonomia and other dysautonomic conditions
BR0113411A (pt) 2000-08-31 2004-01-06 Daiichi Suntory Pharma Co Ltd Processo para a produção do composto de biopterina
AU8852301A (en) 2000-09-01 2002-03-13 Meir S Sacks Compositions and methods for inducing vasorelaxation
DE10043845A1 (de) * 2000-09-06 2002-03-14 Gruenenthal Gmbh Verfahren zur Messung der Aktivität der NO-Synthase
DE10047455A1 (de) 2000-09-26 2002-04-11 Hilti Ag Schraubvorrichtung für ein streifenförmiges Schraubenmagazin
US6689385B2 (en) * 2000-11-03 2004-02-10 Chronorx Llc Formulations for the treatment of insulin resistance and type 2 diabetes mellitus
WO2002042292A2 (en) * 2000-11-20 2002-05-30 Scios Inc. Indol derivative and their use as inhibitors of p38 kinase
UA80393C2 (uk) 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці
US6537992B2 (en) * 2001-01-05 2003-03-25 John D. Parker Regulation of organic nitrate tolerance
TWI241190B (en) * 2001-02-13 2005-10-11 Aventis Pharma Gmbh 4-Fluoro-N-indan-2-yl benzamide and its use as pharmaceutical
US6693094B2 (en) * 2001-03-22 2004-02-17 Chrono Rx Llc Biguanide and sulfonylurea formulations for the prevention and treatment of insulin resistance and type 2 diabetes mellitus
US6500857B1 (en) 2001-08-16 2002-12-31 Nicholas V. Perricone Subcutaneous muscle treatment using electronic stimulation and topical compositions
US20030004125A1 (en) * 2001-06-22 2003-01-02 Hirst David G. Inducible gene
US20030078231A1 (en) * 2001-06-22 2003-04-24 Wilburn Michael D. Orthomolecular sulpho-adenosylmethionine derivatives with antioxidant properties
US20030153972A1 (en) 2002-02-14 2003-08-14 Michael Helmus Biodegradable implantable or insertable medical devices with controlled change of physical properties leading to biomechanical compatibility
CH696628A5 (de) 2002-02-26 2007-08-31 Eprova Ag Verwendung von Folaten zur Herstellung einer Zubereitung geeignet zur Vorbeugung und Behandlung von Entzündungen und entzündungsassoziierter Krankheiten, im Speziellen zur Beeinflussung der
AU2002357798A1 (en) 2002-03-11 2003-09-29 Boyce Thompson Institute For Plant Research Plant nitric oxide synthase
JP4836388B2 (ja) * 2002-03-22 2011-12-14 第一三共株式会社 ｅＮＯＳ発現に起因する疾患の予防または治療薬
US7465555B2 (en) 2002-04-02 2008-12-16 Becton, Dickinson And Company Early detection of sepsis
US20040037809A1 (en) 2002-06-28 2004-02-26 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of interferon beta
WO2004016764A2 (en) 2002-08-16 2004-02-26 Schering Aktiengesellschaft eNOS MUTANTS USEFUL FOR GENE THERAPY
WO2004017955A1 (en) 2002-08-22 2004-03-04 Vasopharm Biotech Gmbh L-arginine containing pharmaceutical composition
US6953799B1 (en) 2002-10-30 2005-10-11 Bach Pharma, Inc. Modulation of cell fates and activities by diketo phthalazines
NL1021892C2 (nl) 2002-11-11 2004-05-12 Tno Detectie van demyelinisatie.
DE10260263A1 (de) * 2002-12-20 2004-07-15 Biocrates Life Sciences Gmbh Verwendung von Tetrahydrobiopterinderivaten zur Behandlung und Ernährung von Patienten mit Aminosäurestoffwechselstörungen
US7732599B2 (en) 2003-11-17 2010-06-08 Biomarin Pharmaceutical Inc. Process for preparing tetrahydrobiopterin and analogs of tetrahydrobiopterin
CA2678124C (en) 2003-11-17 2014-10-07 Merck Eprova Ag Crystalline forms of (6r)-l-erythro-tetrahydrobiopterin dihydrochloride
WO2005049000A2 (en) 2003-11-17 2005-06-02 Biomarin Pharmaceutical Inc. Treatment of phenylketonurias with bh4
CA2566433C (en) 2004-05-11 2013-02-19 Daiichi Asubio Pharma Co., Ltd. Therapeutic agent for bh4-responsive hyperphenylalaninemia
AU2005259961B2 (en) * 2004-06-25 2012-05-17 Board Of Regents, The University Of Texas System Methods and compositions for the treatment of attention deficit hyperactivity disorder and hyperphenylalanemia
JP2008513027A (ja) 2004-09-17 2008-05-01 バイオマリン ファーマシューティカル インコーポレイテッド フェニルアラニンアンモニアーリアーゼの改変体および化学的に修飾された改変体
US20060088566A1 (en) 2004-10-27 2006-04-27 Scimed Life Systems, Inc.,A Corporation Method of controlling drug release from a coated medical device through the use of nucleating agents
WO2006055511A2 (en) 2004-11-17 2006-05-26 Biomarin Pharmaceutical Inc. Stable tablet formulation of tetrahydrobiopterin
US20060194808A1 (en) * 2005-01-14 2006-08-31 Chronorx Llc, An Alaska Limited Liability Company Clinical applications of tetrahydrobiopterin, lipoic acid and their salts and methods of preparing tetrahydrobiopterin bis-lipoate
FR2888499B1 (fr) 2005-07-13 2008-01-04 Oreal Procede de maquillage et/ou de soin cosmetique
KR20100016445A (ko) 2007-04-11 2010-02-12 바이오마린 파머수티컬 인크. 테트라하이드로바이오프테린 투여 방법, 관련 조성물 및 측정 방법

Also Published As

Publication number Publication date
US20180256582A1 (en) 2018-09-13
MXPA06005451A (es) 2007-01-26
US20100009996A1 (en) 2010-01-14
IL175529A0 (en) 2006-09-05
KR20070005550A (ko) 2007-01-10
CA2545584C (en) 2012-10-23
PL3138566T3 (pl) 2022-03-07
HK1094875A1 (zh) 2007-04-13
CN1905863A (zh) 2007-01-31
US20160367558A1 (en) 2016-12-22
EP3977999A1 (en) 2022-04-06
WO2005049000A3 (en) 2005-11-10
EP3138566B1 (en) 2022-01-26
CY1124931T1 (el) 2022-11-25
HUE029533T2 (en) 2017-03-28
US20060040946A1 (en) 2006-02-23
CY1118171T1 (el) 2017-06-28
CA2545584A1 (en) 2005-06-02
EP3138566A1 (en) 2017-03-08
HUE058126T2 (hu) 2022-07-28
DK3138566T3 (da) 2022-01-31
ES2905305T4 (es) 2022-07-13
WO2005049000A2 (en) 2005-06-02
AU2004291149A1 (en) 2005-06-02
JP2007511536A (ja) 2007-05-10
DK1708690T3 (en) 2016-11-07
ES2905305T3 (es) 2022-04-07
US20080090832A1 (en) 2008-04-17
US9433624B2 (en) 2016-09-06
CN1905863B (zh) 2012-03-14
PT1708690T (pt) 2016-09-19
EP1708690B1 (en) 2016-07-20
IL175529A (en) 2016-12-29
AU2004291149B2 (en) 2011-03-24
PT3138566T (pt) 2022-02-02
US20120108599A1 (en) 2012-05-03
PL1708690T3 (pl) 2017-01-31
US8067416B2 (en) 2011-11-29
US9993481B2 (en) 2018-06-12
SI3138566T1 (sl) 2022-04-29
JP2012207029A (ja) 2012-10-25
AU2004291149C1 (en) 2021-01-21
US7566714B2 (en) 2009-07-28
ES2596827T3 (es) 2017-01-12
EP1708690A2 (en) 2006-10-11

Similar Documents

Publication Publication Date Title
BRPI0416566A (pt) tratamento de fenilcetonúrias com bh4
BR0313282A (pt) Composições de inibidor seletivo de ciclooxigenase-2 e um inibidor de anidrase carbÈnica para o tratamento de neoplasia
BRPI0412411A (pt) tetrahidro-1h-pirazol[3,4-c]piridinas substituìdas, composições que as contêm e utilização
CY1107054T1 (el) Ενωσεις διτοσυλικου αλατος κιναζολινης
ATE484508T1 (de) Furylverbindungen
MY172012A (en) Use of dpp iv inhibitors
CY1112790T1 (el) Χρηση μαγιας σεληνιου στην αντιμετωπιση της νοσου αλτσχαιμερ
DE60333746D1 (de) Thienylverbindungen
ATE408601T1 (de) Fredericamycin-derivate
BRPI0408063A (pt) métodos e composições envolvendo mda-7
BR0210013A (pt) Gel oftálmico de pirenzepina
BR0313470A (pt) Combinações terapêuticas de inibidores erbb quinase e terapias antineoplásicas
BRPI0506970A (pt) derivados de alfa-aminoamida úteis no tratamento de distúrbios do trato urinário inferior
ATE439363T1 (de) Imidazo 2,1-b -1,3,4-thiadiazole sulfonamides
ATE275143T1 (de) Verbindungen
TW200642682A (en) A combination of medical drugs to augment the anti-cancer effect of chemotherapy
IS5570A (is) Meðhöndlun á risaeitlingasarkmeini með tálmum viðeitilfrumueiturslóðinni
BRPI0415187A (pt) composição, método para matar bactérias, e, usos de composição e de bacteriófago
DK1411971T3 (da) Anvendelse af lang gentraxin PTX3 til behandling af kvindelig sterilitet
BR0213317A (pt) Uso de um composto, método de tratar um distúrbio relacionado com gastrina, composição farmacêutica, kit, usos de uma composição, e de um inibidor de bomba de próton, métodos de preparar uma composição farmacêutica e um composto, e, composto
NZ528164A (en) Use of flumazenil to produce a medicament for the treatment of cocaine dependency
MXPA06007007A (es) Derivados de prolina usados como ingredientes farmaceuticos activos para el tratamiento de tumores.
PA8646101A1 (es) Compuestos de 4-amino -sustituidos -1,2,3,4-tetrahidroquinolina
HRP20090513T1 (hr) S-mirtazapin, namijenjen liječenju napadaja vrućine
PL372924A1 (en) Combined use of l-carnitine, acetyl l-carnitine and propionyl l-carnitine for the treatment of oligoasthenoteratospermia

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]